Untch, Michael <br/><br/>
Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Sep 2011 
 - 3351-7 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2010.31.4930  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Breast Neoplasms--drug therapy<br/>Carcinoma, Ductal, Breast--drug therapy<br/>Carcinoma, Lobular--drug therapy<br/>Chemotherapy, Adjuvant<br/>Cohort Studies<br/>Cyclophosphamide--administration & dosage<br/>Epirubicin--administration & dosage<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Middle Aged<br/>Neoadjuvant Therapy<br/>Neoplasm Invasiveness<br/>Paclitaxel--administration & dosage<br/>Prospective Studies<br/>Receptor, ErbB-2--metabolism<br/>Remission Induction<br/>Survival Rate<br/>Trastuzumab<br/>Treatment Outcome<br/>Young Adult